NLGN1 and autism: The advent of genome-wide translational profiling (Ingolia et al., 2009) allowed to uncover potential new candidates for therapeutics, whose expression is regulated at the translational level, such as Nlgn1. Given the role of Nlgn1 in autism-related behaviors (Nguyen et al., 2020), we now offer genetic and pharmacological avenues to inhibit Nlgn1 for modulating TSC-related phenotypes (Figure 2; Figure 3; Figure 4).